ASKA gains exclusive Japanese rights to MHB018A, with Minghui receiving $110 million upfront and eligibility for up to $330 ...

Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acquisition of a specialized clinical ...

Figure 1. Ownership flow for the 21 APAC-origin ADCs in Phase 3 or registrational trials. Left: originator. Right: holder of ...

Mr Ng Tian Chong, Chief Executive Officer, Singtel Singapore; Professor Yeoh Khay Guan, Chief Executive, NUHS; and Mr Daniel ...

Differentia Bio, a developer of AI-powered human disease digital twins, announced that therapeutic mechanisms identified by ...